je.st
news
First Presentation of Early Data for Pembrolizumab (MK-3475), Mercks Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
2014-06-01 15:23:00| Merck.com - Corporate News
Dateline City: CHICAGO Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040) Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned Pembrolizumab Announced as New Generic Name for MK-3475 CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of early findings from a Phase 1b study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single-agent (monotherapy) in patients with PD-L1 positive, advanced head and neck cancer. Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
head
early
Category:Biotechnology and Pharmaceuticals